losartan – Page 2 – Communicable Diseases Research

A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19

Research article

Published on 2021-06-172022-10-05
Journal: EClinicalMedicine [Category] 임상,

[키워드] 1:1 95% CI ACE2 Adverse affected all-cause hospitalization analyzed angiotensin receptor blocker ARBs Arm Biotechnology blinded Cell clinically Community contributing to COVID-19 did not reduce disease disrupting Dyspnea Effects Efficacy enrolled enzyme event event rate expected finding functional funding Genomics glomerular filtration rate hospital Hospitalization hospitalizations likelihood losartan Lung injury Mild mitigate multicenter not differ outcome Outpatient outpatients participant Participants partnership Patient Placebo placebo-controlled Primary outcome proportion RAAS Randomized randomized clinical trial RCT Replication SARS-CoV-2 virus secondary significantly statistically Support supported symptom onset symptomatic symptomatic COVID-19 disease temperature treat Treatment treatment group Trial viral entry Viral load was reduced were blinded with COVID-19
[DOI] 10.1016/j.eclinm.2021.100957 [Article Type] Research article

Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial

Randomized Controlled Trial

Published on 2021-06-012022-10-05
Journal: International journal of clinical practice [Category] SARS, 임상,

[키워드] 30-Day mortality 30-day mortality rate administration age clinical trial COVID-19 COVID-19 patient Effect enrolled FIVE group groups hospital Hospital stay hospitalised patient hypertension ICU ICU admission losartan management medication mortality rate outcome p value Patient patient with COVID-19 patients treated patients with COVID-19 per day randomised with COVID-19
[DOI] 10.1111/ijcp.14124 PMC 바로가기 [Article Type] Randomized Controlled Trial

The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy

COVID-19 병인의 분자적 기초, 기존 및 나노의학 요법

Review

Published on 2021-05-212022-09-10
Journal: International Journal of Molecular Sciences [Category] SARS, 유전자 메커니즘,

[키워드] accompanied activate Activation acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus ADP-ribose angiotensin Angiotensin II Apoptosis Basis blocker blockers Cell cell death clinical manifestation clinical manifestations Conventional Coronaviridae family coronavirus coronavirus disease Coronavirus disease-19 COVID-19 COVID-19 pathogenesis cytokine Cytokine storm develop DNA damage Endothelial dysfunction explained Health Organization highly pathogenic humans infect inhibiting investigated involved iron iron oxides losartan macrodomain mechanism mefenamic acid MERS-CoV Middle East Middle East respiratory syndrome Coronavirus molecular mechanisms morbidity morbidity and mortality nanomedicine Necrosis non-structural protein outbreak oxidative burst oxidative stress pandemic PARG PARP pathogenic virus Potential potential therapeutic targets protein 3 quantum dots RAS RAS pathway receptor receptor potential Renin renin-angiotensin system respiratory respiratory distress Respiratory distress syndrome respiratory syndrome coronavirus SARS-CoV SARS-CoV-2 severe acute respiratory syndrome Coronavirus signaling pathway Spread syndrome tannins the Coronaviridae therapeutic agent therapeutic agents therapeutic targets thought trehalose TRPM2 Viral virus virus entry Vitamin D3 World Health Organization
[DOI] 10.3390/ijms22115438 PMC 바로가기 [Article Type] Review

Present and future treatment strategies for coronavirus disease 2019

Review

Published on 2021-04-092022-10-31
Journal: Future Journal of Pharmaceutical Sciences [Category] COVID-19,

Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials

Pharmacology

Published on 2021-03-292022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19

Medicine

Published on 2021-02-172022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] 1:1 Administered adverse event adverse events age angiotensin receptor blocker angiotensin receptor inhibitors ARBs average Bayesian capillary leakage Comorbidities contributing to control group controls Coronavirus disease 2019 COVID-19 COVID−19 cumulative disease severity Efficacy Endpoint enrolled Enrollment hospital discharge Hospitalized illness IMPROVE incidence incidence rate inclusion criteria Inflammation lAbel losartan Lungs male measure open label oral outcome participant Patient Poisson regression post-hoc randomized trial renin-angiotensin system respiratory respiratory compromise Respiratory failure Safe Safety secondary Sex treating treatment group Trial vital status
[DOI] 10.3389/fmed.2021.630209 PMC 바로가기 [Article Type] Medicine

Safety, tolerability, and outcomes of losartan use in patients hospitalized with SARS-CoV-2 infection: A feasibility study

Research Article

Published on 2020-12-302022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS, SARS,

[키워드] Acute kidney injury adverse event AKI blockade Clinical outcome Cohort COVID-19 criteria de novo discharged Enrollment exclusion criteria feasibility hospital hospitalized patient hyperkalemia hypertension ICU admission include inclusion criteria Inflammatory marker inflammatory markers losartan maintain majority mechanical ventilation MOST Nasopharyngeal swab occurred outcome outcomes parameter Patient patients patients hospitalized PCR pilot study polymerase chain positive Prospective prospective cohort Prospective Study provide randomized clinical trials recruitment required retrospective retrospective cohort retrospective cohorts Safety SARS-CoV-2 screened significant changes in single center supplemental oxygen System Tolerability transaminitis with COVID-19
[DOI] 10.1371/journal.pone.0244708 PMC 바로가기 [Article Type] Research Article

Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study

Article

Published on 2020-11-292022-10-30
Journal: Molecules [Category] COVID-19,

Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19

Telmisartan, COVID-19에 대한 잠정적 지오텐신 수용체 차단제 치료제

Article

Published on 2020-11-012022-09-11
Journal: Drug development research [Category] SARS, 임상,

[키워드] ACE2 airway alveolar cell alveolar cells Angiotensin 1-7 Angiotensin II angiotensin receptor blocker Apoptosis ARDS binds cascade China clinical trial complex Complication Concentration coronavirus COVID-19 COVID-19 patient COVID-19 patients Cytokines decrease Degradation disease Election endocytosis Epidemic inflammatory process losartan lung membrane protein New coronavirus Open-label pharmacokinetic physiological pro-inflammatory produced proinflammatory cytokines promote Randomized reducing S protein SARS Coronavirus SARS-CoV-2 SARS-CoV-2 virus telmisartan telmisartan. the S protein therapeutic tissue treating COVID-19 patient turn type 2 alveolar cells virus Wuhan
[DOI] 10.1002/ddr.21679 PMC 바로가기 [Article Type] Article

The Anatomy of the SARS-CoV-2 Biomedical Literature: Introducing the CovidX Network Algorithm for Drug Repurposing Recommendation

Original Paper

Published on 2020-08-202022-10-30
Journal: Journal of Medical Internet Research [Category] COVID-19, MERS,